The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $36 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The National Comprehensive Cancer Network® (NCCN®) has published a brand new NCCN Guidelines for Patients focused on neuroendocrine tumor (NET). These new guidelines offer up-to-date
NET Survivor Finds Hope and Inspiration That’s it—my number is up, Dave McCoy thought when he learned he had neuroendocrine cancer in 2008. A cancer, he
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
Immunotherapy has been called one of the most significant advances in cancer in decades. While this approach may work in some cancers, it is unclear
We are saddened to hear of the passing of Aretha Franklin, the Queen of Soul, who died of a pancreatic neuroendocrine tumor (pNET). She was
New Potential NET Treatment under Investigation It is hard for doctors to know which patients will respond to which therapies. New approaches in personalized medicine
Understanding the grade and stage of neuroendocrine cancer and how that relates to prognosis.
The U.S. Food and Drug Administration (FDA) approved iobenguane I 131, an intravenous radiotherapeutic, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or
Natural or man-made disasters often occur with little or no notice. Being prepared for a disaster during COVID-19 is important for everyone, but cancer patients
David Van Bibber calls his neuroendocrine cancer diagnosis a blessing in disguise.it. Since his 2010 diagnosis at the age of 32, David’s priorities and perspectives have changed. As a result, he has invested more deeply in his health, his family, and his community. Now he is reaping the rewards of that investment and finding daily joy in his life.
